IDH1 and central nervous system cancer: That being said, our RCAS/Ntv-a Atrx KO model, though lacking mutant IDH1, closely mirrors the natural progression of low-grade gliomas in humans and corroborates the immunological effects of ATRX loss noted in human gliomas and the CT2A Atrx KO model.